EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer

Stefania Crucitta, Martina Ruglioni, Claudia Novi, Mascia Manganiello, Roberta Arici, Iacopo Petrini, Eleonora Pardini, Federico Cucchiara, Federica Marmorino, Chiara Cremolini, Stefano Fogli, Romano Danesi und 1 weitere

Clinica Chimica Acta · 2023

DOI: 10.1016/j.cca.2023.117239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinica Chimica Acta, 2023. Verfasst von Stefania Crucitta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cell-Free Nucleic Acids, Colorectal Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Highly sensitive technologies are available for the molecular characterization of solid tumors, including digital PCR (dPCR). Liquid biopsy, based on the analysis of cell-free DNA (cfDNA), is often used to assess EGFR or RAS alterations in lung and colorectal cancers. Our study aimed to compare the results of two different dPCR platforms for the detection of mutations in cfDNA. METHODS: Plasma samples from lung and colorectal cancer patients collected as per routine procedures have been tested. cfDNA Was extracted from plasma, and samples were screened on the droplet digital PCR (ddPCR, BioRad) and solid dPCR QIAcuity (Qiagen). RESULTS: A total of 42 samples were analyzed, obtained from 20 Non-Small Cell Lung Cancer (NSCLC) patients carrying an EGFR or a KRAS mutation on tissue at diagnosis, and from 22 samples of colorectal cancer (CRC) patients, 10 of which presenting a KRAS mutation. EGFR mutation detection was 58.8% for ddPCR and 100% for dPCR (κ = 0.54; 95% CI, 0.37-0.71), compared to tissue results. The detection rate for RAS mutations was 72.7% for ddPCR and 86.4% for dPCR (κ = 0.34; 95% CI, 0.01-0.68), compared to tissue results. CONCLUSIONS: This study showed moderate agreement between dPCR and ddPCR. Sampling effect or threshold settings may potentially explain the differences in the cfDNA data between the two different platforms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCell-Free Nucleic AcidsColorectal NeoplasmsHumansProto-Oncogene Proteins p21(ras)Liquid BiopsyPolymerase Chain ReactionMutationLungErbB Receptors

Stichwörter der Autor:innen

Colorectal cancerDigital PCRLiquid biopsyLungcfDNA

Substanzen

Proto-Oncogene Proteins p21(ras)Cell-Free Nucleic AcidsErbB Receptors

Autor:innen und Institutionen

  • Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Unit of Pneumology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: romano.danesi@unipi.it.

Zitieren

APA

Crucitta, S., Ruglioni, M., Novi, C., Manganiello, M., Arici, R., Petrini, I., Pardini, E., Cucchiara, F., Marmorino, F., Cremolini, C., Fogli, S., Danesi, R., & Del Re, M. (2023). Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer. Clinica Chimica Acta. https://doi.org/10.1016/j.cca.2023.117239

Vancouver

Crucitta S, Ruglioni M, Novi C, Manganiello M, Arici R, Petrini I, et al. Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer. Clinica Chimica Acta. 2023. doi:10.1016/j.cca.2023.117239

BibTeX
@article{Crucitta2023,
  author = {Crucitta, Stefania and Ruglioni, Martina and Novi, Claudia and Manganiello, Mascia and Arici, Roberta and Petrini, Iacopo and Pardini, Eleonora and Cucchiara, Federico and Marmorino, Federica and Cremolini, Chiara and Fogli, Stefano and Danesi, Romano and Del Re, Marzia},
  title = {Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer},
  journal = {Clinica Chimica Acta},
  year = {2023},
  doi = {10.1016/j.cca.2023.117239}
}
Kostenlos starten →